Ismaiel Abdulrahman, Foucambert Paul, Ismaiel Mohamed, Leucuta Daniel C, Popa Stefan-Lucian, Baban Adriana, Dumitrascu Dan L
2nd Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Department of General Surgery, Altnagelvin Hospital, Londonderry, United Kingdom.
J Neurogastroenterol Motil. 2024 Oct 30;30(4):387-396. doi: 10.5056/jnm23159.
BACKGROUND/AIMS: In recent years, the presence of alexithymia in patients with irritable bowel syndrome (IBS) has gained more attention, and several studies have evaluated this relationship. However, no clear conclusion has been reported yet. Therefore, we conducted a systematic review and meta-analysis to better understand the association between IBS and alexithymia.
We performed a systematic search on the medical databases PubMed, EMBASE, and Scopus using predefined keywords to identify observational studies assessing the association between IBS and alexithymia. The included studies diagnosed IBS using the Rome criteria, and alexithymia was evaluated using the 20-item Toronto Alexithymia Scale (TAS-20) score. We used The Newcastle-Ottawa Scale to evaluate the quality of included studies. The primary summary outcome was the mean difference in TAS-20 scores.
We included 7 studies involving 1,513 individuals in our qualitative analysis, with 6 of them included in our quantitative analysis. All studies were considered to be of satisfactory quality according to the Newcastle-Ottawa Scale criteria. We found significantly higher TAS-20 scores in IBS patients compared to controls (8.063 [95% CI, 2.554-13.572]). However, no significant mean difference in TAS-20 scores was observed in IBS vs inflammatory bowel disease patients (0.884 [95% CI -2.536-4.304]).
We demonstrated that IBS is associated with an increased risk of developing alexithymia. However, our study did not show a significant difference in TAS-20 scores between patients with IBS compared to inflammatory bowel disease.
背景/目的:近年来,肠易激综合征(IBS)患者中述情障碍的存在受到了更多关注,多项研究对这种关系进行了评估。然而,尚未有明确结论报道。因此,我们进行了一项系统评价和荟萃分析,以更好地了解IBS与述情障碍之间的关联。
我们使用预定义关键词在医学数据库PubMed、EMBASE和Scopus上进行系统检索,以识别评估IBS与述情障碍之间关联的观察性研究。纳入的研究使用罗马标准诊断IBS,并使用20项多伦多述情障碍量表(TAS-20)评分评估述情障碍。我们使用纽卡斯尔-渥太华量表评估纳入研究的质量。主要汇总结果是TAS-20评分的平均差异。
我们的定性分析纳入了7项研究,共1513名个体,其中6项纳入了定量分析。根据纽卡斯尔-渥太华量表标准,所有研究的质量均被认为令人满意。我们发现,与对照组相比,IBS患者的TAS-20评分显著更高(8.063 [95% CI,2.554 - 13.572])。然而,IBS患者与炎症性肠病患者的TAS-20评分未观察到显著的平均差异(0.884 [95% CI -2.536 - 4.304])。
我们证明IBS与发生述情障碍的风险增加相关。然而,我们的研究未显示IBS患者与炎症性肠病患者在TAS-20评分上有显著差异。